Please see below for the Educational Materials required to be implementated as part of Risk Minimisation Activity for the respective products.

If any adverse events should occur in your patients, including any possible side effects not listed in the brochures. Please kindly report it directly to Roche Hong Kong Drug Safety atBy reporting side affects you can help provide more information on the safety of this medicine.

Please do not share this website with non-Healthcare Professionals or to the public. Please download the patient materials before sharing to your patients. If hardcopies are required, please do not hesitate to request them through Roche Hong Kong Medical Information at

The HCP guide is for your reference to support you when utilizing Hemlibra, as well as highlight the important identified risks for Hemlibra.

As Hemlibra affects assays for activated partial thromboplastin time (aPTT) and all assays based on aPRR, to reduce the risk of life-threatening bleeding due to unreliable standard coagulation tests and inhibitor assays, the Laboratory Professional Guide attached should be sent along with patient’s lab tests to the laboratory to inform them of the potential interaction with test results.

This checklist is to be completed by the Physician for all female patients prescribed Roaccutane and kept with patient notes to document compliance with the Roaccutane Pregnancy Programme.

Checklist for Pharmacist for guidance when dispensing Roaccutane

處方者應為所有處方保膚靈®的女性患者完成評估清單,並將這份清單連同患者其他資料共同保存以作保膚靈®的懷孕預防計 劃證明。


Reminder card for patient's use


© Roche Hong Kong This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.Remark: This statement has been translated into Chinese. In case of inconsistency between the English and Chinese versions, the English version shall prevail.